{"groups":[{"description":"Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for standard risk patients PFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.","id":"FG000","title":"Auto-Auto Standard Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients","id":"FG001","title":"Auto-Allo Standard Risk"},{"description":"Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for high risk patients\n\nPFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.","id":"FG002","title":"Auto-Auto High Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients","id":"FG003","title":"Auto-Allo High Risk"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"436"},{"groupId":"FG001","numSubjects":"189"},{"groupId":"FG002","numSubjects":"48"},{"groupId":"FG003","numSubjects":"37"}],"type":"STARTED"},{"achievements":[{"comment":"Participants that were alive and free of disease progression at the end of follow-up (3 years)","groupId":"FG000","numSubjects":"178"},{"comment":"Participants that were alive and free of disease progression at the end of follow-up (3 years)","groupId":"FG001","numSubjects":"71"},{"comment":"Participants that were alive and free of disease progression at the end of follow-up (3 years)","groupId":"FG002","numSubjects":"14"},{"comment":"Participants that were alive and free of disease progression at the end of follow-up (3 years)","groupId":"FG003","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"258"},{"groupId":"FG001","numSubjects":"118"},{"groupId":"FG002","numSubjects":"34"},{"groupId":"FG003","numSubjects":"24"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants were enrolled between December 2003 and March 2007 from 37 different transplant centers."}